Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net loss	$ (21,244)	$ (23,647)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,713	1,826
Operating lease right-of-use assets	259	100
Accretion/accrual of term loan discounts and debt issuance costs	180	419
Depreciation and amortization	88	28
Loss on disposal of property, equipment and leasehold improvements	10
Accretion of available-for-sale marketable securities, net	(1,774)	(268)
Change in fair value of term loan derivative liability		147
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,935)	(579)
Accounts payable	(1,676)	(527)
Accrued expenses and other liabilities	28	657
Net cash used in operating activities	(25,351)	(21,844)
Investing activities:
Proceeds from maturities of available-for-sale marketable securities	55,679	2,001
Purchases of available-for-sale marketable securities	(8,981)	(61,025)
Purchases of property, equipment and leasehold improvements	(115)	(43)
Net cash provided by (used in) investing activities	46,583	(59,067)
Financing activities:
Proceeds from at-the-market sales, net of commissions	1,710
Proceeds from exercises of stock options	73	139
Proceeds from employee stock purchase plan	33	23
Repayments of term loan, term loan final fee and prepayment premium	(9,409)	(4,083)
Payments of offering costs	(200)	(195)
Payments of finance lease	(63)
Proceeds from sale of common stock and warrants in public offering and private placement, net of issuance costs		103,010
Proceeds from exercises of warrants		11,782
Payments of financing costs of term loan		(21)
Net cash (used in) provided by financing activities	(7,856)	110,655
Net increase in cash and cash equivalents	13,376	29,744
Cash and cash equivalents at beginning of period	12,589	36,830
Cash and cash equivalents at end of period	$ 25,965	$ 66,574